Sign in
TerminatedPhase 1

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Key facts

Who runs it
Mirati Therapeutics Inc.
Where
Baltimore, Boston, Fairfax, Grand Rapids, Houston, Lady Lake, Nashville, New Haven, New York, Phoenix, San Antonio, and Seattle, United StatesSee the 14 sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
63 people enrolled
Started
6 Mar 2023
Ended
10 Mar 2025
Type of study
Interventional, 2 groups
Treatments tested
  • MRTX1133
Record updated
6 April 2025
Why it stopped
Formulation challenges

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Histologically confirmed diagnosis of a solid tumor malignancy harboring KRAS G12D mutation in tumor tissue or ctDNA
  • Unresectable or metastatic disease
  • Patients must have received standard therapies appropriate for their tumor type and stage; first-line treatment for PDAC for certain cohorts
  • Presence of tumor lesions to be evaluated per RECIST v1.1:; in the Phase 1 dose escalation cohorts, patients must have measurable or evaluable disease; in the Phase 1b and Phase 2 cohorts, patients must have measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ function
  • Age ≥ 18 years

Who cannot take part

  • Prior treatment with a KRAS G12D inhibitor (Phase 1b \& Phase 2 only)
  • History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment
  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow oral medications
  • History of malignant small bowel obstruction
  • Cardiac abnormalities
  • Active brain metastases or carcinomatous meningitis

Where in United States

  • Baltimore, MarylandHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Fairfax, VirginiaHospital not named in the registry
  • Grand Rapids, MichiganHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Lady Lake, FloridaHospital not named in the registry
  • Nashville, TennesseeHospital not named in the registry
  • New Haven, ConnecticutHospital not named in the registry
  • New YorkHospital not named in the registry
  • Phoenix, ArizonaHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • Seattle, WashingtonHospital not named in the registry

About the trial

What the trial wants to find out

A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.

The 2 groups in the trial

  • Phase 1/1BTreatment being tested

    Dose Escalation/Evaluation

    Treatment: MRTX1133

  • Phase 2Treatment being tested

    MRTX1133 recommended Phase 2 dose administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12D mutation to include the following: NSCLC, PDAC, CRC, Other Solid Tumors

    Treatment: MRTX1133

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Publications
Record updated
6 April 2025